Bayer Aktiengesellschaft (BAYN.DE)
| Previous Close | 26.90 |
| Open | 27.05 |
| Bid | 27.39 x 28400 |
| Ask | 27.40 x 2100 |
| Day's Range | 26.97 - 27.54 |
| 52 Week Range | 24.96 - 60.15 |
| Volume | |
| Avg. Volume | 4,773,188 |
| Market Cap | 26.928B |
| Beta (5Y Monthly) | 0.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.99 |
| Earnings Date | May 14, 2024 |
| Forward Dividend & Yield | 0.11 (0.41%) |
| Ex-Dividend Date | Apr 29, 2024 |
| 1y Target Est | 34.80 |
ZacksRoche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.
FortunePharmaceutical giant Bayer’s manager cull will likely affect thousands of bosses—and the aspirin inventor thinks it will help its ‘brilliant’ Gen Z grads to thrive
Bayer currently has more than twelve tiers between management and its customers in some departments, and the aim of CEO Bill Anderson is to reduce that to around five or six.
- Reuters
Bayer confirms 2024 outlook despite slow start for agriculture, consumer health units
FRANKFURT (Reuters) -Bayer confirmed its full-year forecast for earnings and cash flow on Monday despite slow business at its crop science and consumer health divisions. "Our Crop Science and Consumer Health divisions expect a slow start to the year due to market dynamics, but we feel confident in our full-year targets and the direction of our businesses," CEO Bill Anderson said in his speech for the April 26 annual general meeting (AGM), which was posted on the company's website on Monday. The CEO reiterated that 2024 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-off items and currency swings, would decline between 3% and 9% and that free cash flow would reach 2-3 billion euros ($2.1-$3.2 billion) up from 1.3 billion last year.
